BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33555033)

  • 1. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
    Samant TS; Yang S; Miller M; Ji Y
    J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
    Lu Y; Yang S; Ho YY; Ji Y
    J Clin Pharmacol; 2021 Aug; 61(8):1054-1068. PubMed ID: 33713359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
    Ji Y; Abdelhady AM; Samant TS; Yang S; Rodriguez Lorenc K
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):855-866. PubMed ID: 32706937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribociclib: First Global Approval.
    Syed YY
    Drugs; 2017 May; 77(7):799-807. PubMed ID: 28417244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
    Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
    Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
    Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.
    James AD; Schiller H; Marvalin C; Jin Y; Borell H; Roffel AF; Glaenzel U; Ji Y; Camenisch G
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00599. PubMed ID: 32524755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
    Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Burris HA
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
    Sane R; Malhi V; Sutaria DS; Cho E; Twomey P; Craggs C; Wang J; Harris A; Musib L
    J Clin Pharmacol; 2022 Feb; 62(2):171-181. PubMed ID: 34402068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
    Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
    Csonka D; Hazell K; Waldron E; Lorenzo S; Duval V; Trandafir L; Kobalava ZD
    J Clin Pharmacol; 2016 Mar; 56(3):316-23. PubMed ID: 26183800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
    Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
    Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials.
    Ji Y; Yartsev V; Quinlan M; Serra P; Wang Y; Chakraborty A; Miller M
    Clin Pharmacokinet; 2023 Mar; 62(3):493-504. PubMed ID: 36800111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.